Health Care & Life Sciences » Biotechnology | Tissue Regenix Group PLC

Tissue Regenix Group PLC | Balance Sheet

Fiscal year is January-December. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
24,206.00
18,483.00
10,257.00
8,173.00
16,423.00
7,816
Total Accounts Receivable
656.00
807.00
1,455.00
2,658.00
4,168.00
4,751
Inventories
-
-
34.00
661.00
2,872.00
2,330
Other Current Assets
51.00
320.00
492.00
472.00
-
-
Total Current Assets
24,913.00
19,610.00
12,238.00
11,964.00
23,463.00
14,897
Net Property, Plant & Equipment
238.00
472.00
435.00
1,087.00
2,994.00
2,828
Intangible Assets
-
-
-
550.00
19,305.00
19,938
Total Assets
25,151.00
20,082.00
12,673.00
13,601.00
45,762.00
37,663
Accounts Payable
205.00
368.00
312.00
618.00
1,519.00
Other Current Liabilities
480.00
736.00
783.00
1,447.00
3,262.00
Total Current Liabilities
685.00
1,104.00
1,095.00
2,065.00
4,781.00
Deferred Taxes
-
-
-
-
824.00
Other Liabilities
-
-
-
-
635.00
Total Liabilities
685.00
1,104.00
1,095.00
2,065.00
6,240.00
Common Equity (Total)
24,466.00
18,978.00
11,578.00
11,745.00
39,931.00
Total Shareholders' Equity
24,466.00
18,978.00
11,578.00
11,745.00
39,931.00
Total Equity
24,466.00
18,978.00
11,578.00
11,536.00
39,522.00
Liabilities & Shareholders' Equity
25,151.00
20,082.00
12,673.00
13,601.00
45,762.00
Accumulated Minority Interest
-
-
-
209.00
409.00

About Tissue Regenix Group

View Profile
Address
Astley Lane Industrial Estate
Leeds Yorkshire LS26 8XT
United Kingdom
Employees -
Website http://tissueregenix.com
Updated 07/08/2019
Tissue Regenix Group Plc is a medical technology company, which develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine. Its patented decellularisation technology removes DNA and other cellular material from animal and human tissue leaving a cellular tissue scaffold, which is not rejected by the patient's body which can then be used to repair diseased and worn out body parts. The potential applications of this process address clinical needs such as vascular disease, heart valve replacement and knee repair.